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Abstract
Background: Ependymal cells form a protective monolayer between the brain parenchyma and
cerebrospinal fluid (CSF). They possess motile cilia important for directing the flow of CSF through
the ventricular system. While ciliary beat frequency in airway epithelia has been extensively studied,
fewer reports have looked at the mechanisms involved in regulating ciliary beat frequency in
ependyma. Prior studies have demonstrated that ependymal cells express at least one purinergic
receptor (P2X7). An understanding of the full range of purinergic receptors expressed by
ependymal cells, however, is not yet complete. The objective of this study was to identify purinergic
receptors which may be involved in regulating ciliary beat frequency in lateral ventricle ependymal
cells.
Methods: High-speed video analysis of ciliary movement in the presence and absence of purinergic
agents was performed using differential interference contrast microscopy in slices of mouse brain
(total number of animals = 67). Receptor identification by this pharmacological approach was
corroborated by immunocytochemistry, calcium imaging experiments, and the use of two separate
lines of knockout mice.
Results: Ciliary beat frequency was enhanced by application of a commonly used P2X7 agonist.
Subsequent experiments, however, demonstrated that this enhancement was observed in both
P2X7+/+ and P2X7-/- mice and was reduced by pre-incubation with an ecto-5'-nucleotidase inhibitor.
This suggested that enhancement was primarily due to a metabolic breakdown product acting on
another purinergic receptor subtype. Further studies revealed that ciliary beat frequency
enhancement was also induced by adenosine receptor agonists, and pharmacological studies
revealed that ciliary beat frequency enhancement was primarily due to A2B receptor activation. A2B
expression by ependymal cells was subsequently confirmed using A2B-/-/β-galactosidase reporter
gene knock-in mice.
Conclusion: This study demonstrates that A2B receptor activation enhances ciliary beat frequency
in lateral ventricle ependymal cells. Ependymal cell ciliary beat frequency regulation may play an
important role in cerebral fluid balance and cerebrospinal fluid dynamics.
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The cerebral ventricles are lined by a layer of ciliated
ependymal cells that play an important role in cerebral
fluid balance [1]. It has been estimated that each ependy-
mal cell possesses 20-30 motile cilia, which are 8-20 μm
in length with a 9 + 2 microtubule structure. Their ciliary
tufts are organized in a manner consistent with the direc-
tion of cerebrospinal fluid (CSF) flow [2]. Abnormalities
in ciliogenesis or ciliary function are frequently associated
with hydrocephalus [3-11], and ependymal denudation
can be observed in cases of communicating hydrocepha-
lus [12]. Despite the increased recognition that ependy-
mal cells are important for regulating CSF dynamics, only
a few reports have specifically looked at the extracellular
signaling mechanisms involved ependymal cell ciliary
beat frequency modulation.
Nelson and Wright (1974) noted enhancement of frog
brain ependymal ciliary beat frequency by ATP (adenos-
ine 5'-triphosphate), cAMP (adenosine 3',5'-cyclic mono-
phosphate), theophylline, and acetylcholine, as well as
decreases in ciliary beat frequency by a number of other
agents, using an in vitro preparation [13]. A later study by
Nguyen et al. (2001) observed an ATP-mediated decrease
in ciliary beat frequency, as well as a serotonin-mediated
increase, in 4th ventricle ependymal cells in cultured rat
brain slices and acutely isolated ependymal cells [14].
Finally, reports from O'Callaghan et al. have demon-
strated that both hydrogen peroxide and bacterial pneu-
molysin inhibit ciliary beat frequency in rat brain
ependymal cells [15,16].
Recent work from our laboratory demonstrated that the
purinergic P2X7 receptor is widely expressed on ependy-
mal cells [17]. Furthermore, receptor activation leads to
increases in intracellular calcium ([Ca2+]i) both in the
soma and cilia. Working under the hypothesis that the
P2X7 receptor may be involved in regulating ciliary beat
frequency, we have conducted experiments using high-
speed video capture and differential interference contrast
(DIC) microscopy to investigate potential modulation of
ciliary beat frequency by purinergic agonists. These exper-
iments have demonstrated, however, that the adenosine
A2B receptor is primarily responsible for ciliary beat fre-
quency enhancement by these agents. Further experi-
ments using A2B-/-/β-galactosidase reporter gene knock-in
mice confirmed this observation and also demonstrated a
residual P2X7-mediated component to ciliary beat fre-
quency enhancement.
Methods
Slice preparation
Research protocols were approved by the Yale University
Institutional Animal Care and Use Committee (approval
#A3230-01). C57BL/6 mice (n = 48; Jackson Laboratories,
Bar Harbor, ME, USA), CD1 mice (n = 7; Charles River
Laboratories, Wilmington, MA, USA), P2X7 knockout
mice (n = 5; P2rx7tm1Gab, Jackson Laboratories, [18]), and
A2B knockout mice (n = 7, [19]) were used for the present
experiments. Mean age of animals was 24.3 ± 1.0 days
(range 13-39). Animals were anesthetized with pentobar-
bital, 50 mg/kg, intraperitoneal (IP); after craniotomy and
dissection, horizontal brain slices (250-300 μm) were pre-
pared in chilled (4°C) dissection solution (in mM): 83
NaCl, 73 sucrose, 2.5 KCl, 2.7 MgCl2, 1.7 CaCl2, 1.2
NaH2PO4, 10 glucose, 26 NaHCO3, pH 7.4 and bubbled
with 95% O2/5% CO2 using a series 1000 Vibratome (The
Vibratome Company, St. Louis, MO, USA). Slices were
incubated for >1 h in artificial CSF (aCSF) at room tem-
perature (in mM): 125 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2,
1.25 NaH2PO4, 10 glucose, and 26 NaHCO3, pH 7.4 and
bubbled with 95% O2/5% CO2. Slices were transferred to
a recording chamber and superfused (~1 ml/min) with
aCSF and bubbled with 95% O2/5% CO2 at room temper-
ature. Experiments were performed on an upright micro-
scope (Olympus BX51WI; Olympus, Center Valley, PA,
USA) under phase-contrast optics (60× objective, NA 0.9)
and a 2× teleconverter. Ciliated ependymal cells were vis-
ually identified along the subventricular zone (SVZ) bor-
der lining the lateral surface of the lateral ventricles (e.g.
Fig. 1A). Agonists and antagonists were bath applied, and
only one exposure or experimental condition was permit-
ted per slice. After preliminary time course experiments
(see Fig. 1B), ciliary beat frequency measurements were
analyzed at baseline then five min after agonist applica-
tion unless otherwise indicated. Antagonists and inhibi-
tors were always pre-applied (range 4-15 min), depending
on the site of action (extracellular versus intracellular),
and our prior experience using these agents in patch
clamp experiments [17]; they were also present during
agonist applications (for antagonist experiments only) to
decrease the possibility of antagonist washout.
Ciliary Beat Frequency Analysis
Ciliary beat frequency on lateral ventricle ependymal cells
was analyzed using modifications of a previously pub-
lished approach [15]. High-speed video acquisition of cil-
iary beat frequency was performed using a Pioneer A640-
210 gm GigE camera (Basler Vision Technologies, Exton,
PA, USA) with StreamPix3 software (Norpix Inc., Mon-
treal, Quebec, Canada). One-sec videos along the epend-
ymal wall were digitally acquired to a Dell Computer
(Round Rock, TX, USA) at 200 frames per sec (fps). Files
were converted to multi-TIFF stacks of 200 images and
imported into ImageJ (NIH, Bethesda, MD, USA), where
the stacks were re-sliced along a line placed across the cil-
iary tuft, thus creating pseudo-line scans. Ciliary beat fre-
quency was calculated by measuring peak-to-peak
intervals of periodicity evident in the pseudo-line scanPage 2 of 11
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representing 1/200 of a second.
Ten periods were measured for each video, representing
cilia from 3-6 ependymal cells on average. Analysis was
conducted blinded to experimental conditions and with
randomized file names and chronology, thus decreasing
potential bias. Ciliary beat frequency data from pharma-
cological studies are presented using the following two
equations:
Comparison of our methodology to separate manual
counting of ciliary beat frequency in the 1 sec video play-
back, as well as repeat analysis of duplicate files (with ran-
domized names and chronology), yielded a strong
correlation as determined by linear regression (r2 = 0.905
and 0.95 respectively; data not shown).
Ciliary beat frequency of pixels in wave period= 1 200/(# / )
(1)
Ciliary beat frequency normalized beat frequency during ( ) = agonist application beat frequency at baseline÷
(2)
Ciliary beat frequency  increase beat frequency durin(% ) ((= g agonist application beat frequency at baseline)-1)*100÷
(3)
Purinergic enhancement of ciliary beat frequency is observed in both P2X7+/+ and P2X7-/- miceFigure 1
Purinergic enhancement of ciliary beat frequency is observed in both P2X7+/+ and P2X7-/- mice. (A) DIC image of 
an ependymal cell. (Bar = 12 μm) Cilia are noted (*). (B) Beat frequency (normalized) during 300 μM BzATP application in slices 
from P2X7+/+ (filled circles/solid line; n = 5) and P2X7-/- (open squares/dotted line; n = 4) mice. Responses from P2X7+/+ and 
P2X7-/- animals were not significantly different. (C) Beat frequency (% increase) in slices from P2X7+/+ (n = 5) and P2X7-/- (n = 4) 
mice after 5 min 300 μM BzATP application. Decreases (P < 0.05) were observed in the presence of the ecto-5'-nucleotidase 
inhibitor αβmADP (50 μM) in P2X7+/+ (n = 6) and P2X7-/- (n = 6) mice. BBG significantly decreased BzATP-induced enhance-
ment in P2X7+/+ mice (n = 4). (D) Beat frequency (% increase) in P2X7+/+ mice during application of 100 μM ATP (P < 0.05 com-
pared to no drug control; n = 4). The P2Y receptor antagonist suramin (200 μM; n = 5) did not significantly reduce 
enhancement seen with 100 μM ATP. Beat frequency was not enhanced by the P2Y2/P2Y4 agonist UTP (100 μM; n = 2). (E) 
Beat frequency enhancement with increasing concentrations of adenosine (filled circles; n = 4-5) and NECA (open squares; n = 
4-8). A significant difference was observed between NECA and adenosine at 1 μM. *: P < 0.05 for all panels, data are means ± 
SEM. The n value indicates number of slices tested.Page 3 of 11
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Immunocytochemistry was performed according to previ-
ously described protocols [17]. Briefly, animals were anes-
thetized with pentobarbital (50 mg/kg, IP), then fixed by
transcardiac perfusion with phosphate buffered saline
(PBS; 20 ml) followed by 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA, USA) in PBS (30 ml).
The brains were removed and post-fixed in 4% parafor-
maldehyde in PBS (24 h, 4°C). 100 μm slices were then
made using a series 1000 Vibratome. Slices were washed
with 0.05 M tris base in 9% NaCl at pH 7.4 (TBS), perme-
abilized in TBS + 0.1% Triton X-100 (TBST), blocked in
TBST + 10% normal donkey serum, and then incubated
overnight with primary antibody at 4°C. Antibodies
included 1:100 rabbit anti-S100β (Sigma, St. Louis, MO,
USA), 1:1000 mouse anti-β-galactosidase (Sigma), 1:100
mouse anti-A2A (Upstate, Millipore, Billerica, MA, USA),
and 1:100 rabbit anti-A2B (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). After washing (3 × 45 min in TBST),
slices were incubated 2 h at room temperature in second-
ary antibody solution (donkey, Alexa Fluor® 488, 594,
633, and/or 647; Invitrogen, Carlsbad, CA, USA). After 3
× 30 minute washes in TBS they were mounted and cover-
slipped with Prolong Gold Antifade Reagent (Invitrogen)
with or without 1:1000 DAPI (2-(4-amidinophenyl)-6-
indolecarbamidine dihydrochloride; Invitrogen).
β-galactosidase (β-gal) expression analysis in A2B reporter 
mice
β-gal expression in A2B-/-/β-gal reporter gene knock-in
mice was studied according to a previously published pro-
tocol [19]. Mice were anesthetized with isoflurane, per-
fused with 20 ml PBS through the left heart ventricle, and
perfusion fixed with 30 ml 2% paraformaldehyde in PBS.
Brains were removed, cut into 2 mm coronal sections con-
taining intact lateral ventricular walls, and stained for β-
gal activity using X-gal staining solution: 5 mM
K3Fe(CN)6, 5 mM K4Fe(CN)6·2 mM MgCl2 in PBS, with a
final concentration of 1 mg/ml 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-gal, American Bioana-
lytical; Nantick, MA, USA), then incubated at 37° for 6-12
h, rinsed in PBS, and stored in 4% paraformaldehyde. Sec-
tions were embedded in low melting point agarose
(American Bioanalytical), resectioned to 100 μm, and
mounted directly onto slides or used for subsequent
immunocytochemistry as previously described.
Calcium imaging
Acute mouse brain slices were loaded with the Ca2+-sensi-
tive dye Fluo-4 AM (Invitrogen; 4 μM in dimethyl sulfox-
ide (DMSO) with 20% Pluronic F-127) using ependyma-
directed applications by a Picospritzer II (1-2 psi; Parker
Instrumentation, Cleveland, OH, USA). Slices were
washed for a minimum of 10 min before recording. The
Ca2+ imaging system consisted of a confocal laser scan-
ning microscope (Olympus) with a 60× water objective
(NA 0.9) and Fluoview software (Olympus). Agonists in
Ca2+ imaging experiments were focally applied using a
Picospritzer II (as above). Calcium data were analyzed
using the Calsignal program [20].
Genotyping
WT C57BL/6 (P2X7+/+), P2X7-/-, and A2B-/-/β-gal mice were
maintained as separate, homozygous colonies. Genotyp-
ing was performed on all animals used in knockout-
related experiments to survey for any potential errors in
animal husbandry [17,19].
The A2B-/-/β-gal mice were previously bred onto a pure
C57BL/6J background strain [21]. P2X7-/- mice were previ-
ously backcrossed to C57BL/6 mice for 7 generations
(Jackson Laboratories, JAX® Mice Database; http://
jaxmice.jax.org). We cannot exclude the possibility, how-
ever, that additional genetic variation exists between the
C57BL/6 (P2X7+/+), P2X7-/-, and A2B-/-/β-gal strains.
Reagents
Salts used for aCSF solution, as well as adenosine,
αβmADP, ATP, BzATP, dipyridamole, NBMPR, phlo-
ridzin, and UTP were purchased from Sigma. CGS 21680,
IB-MECA, 2'MeCCPA, MRS 1754, NECA, and PSB 603
were purchased from Tocris (Ellisville, MO, USA). A list of
all drugs used in the present experiments is included in
Table 1.
Statistics
Data were analyzed and presented in SigmaPlot 8.0 (SPSS,
Chicago, IL, USA). Statistical significance was determined
using the Student's t-test (P < 0.05). Data are presented as
mean ± standard error of the mean (SEM) unless other-
wise indicated. Reported n values refer to the number of
slices tested (with each slice including 10 ciliary beat fre-
quency measurements; see above).
Results
Purinergic enhancement of ciliary beat frequency is 
present in P2X7+/+ and P2X7-/- mice and is induced by non-
selective adenosine receptor agonist
Given our prior demonstration of ciliary (and somatic)
localization of P2X7 receptors on lateral ventricle ependy-
mal cells [17], we first sought to determine whether
BzATP (a commonly used P2X7 agonist) was also able to
induce changes in ciliary beat frequency. Ciliated ependy-
mal cells were visualized in horizontal mouse brain slices
using high-speed DIC microscopy (Fig. 1A; see Methods
for ciliary beat frequency calculations). Average baseline
ciliary beat frequency was 11.4 ± 0.2 Hz (n = 160) in wild-
type mice. While 300 μM BzATP (Fig. 1B) was able to
increase ciliary beat frequency in C57BL/6 wild-type
(P2X7+/+) mice, a similar increase was also observed inPage 4 of 11
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application of 300 μM BzATP in P2X7+/+ mice (58.9 ±
3.4%) and in P2X7-/- mice (58.6 ± 4.1%). These responses
were not significantly different.
Preincubation with 100 nM brilliant blue G (BBG; a P2X7
antagonist), however, did result in a partial inhibition of
BzATP-induced beat frequency enhancement in P2X7+/+
animals (Fig. 1C; 46.1 ± 4.4%). This suggests that P2X7
may contribute only a minor component to BzATP-
induced enhancement in wild-type mice. A significant
decrease in BzATP-induced enhancement, P < 0.05, how-
ever, was also observed when the ecto-5'-nucleotidase
inhibitor αβmADP (50 μM, [22]) was present in the bath
solution for both P2X7+/+ mice (35.1 ± 3.8%) and P2X7-/-
mice (27.2 ± 3.2%, Fig. 1C) thus providing evidence that
enhancement may be dependent on a metabolic break-
down product of BzATP.
To determine if either P2Y receptors or adenosine recep-
tors are involved in ciliary beat frequency enhancement,
experiments were performed using ATP, UTP, and a P2Y
antagonist suramin (Fig. 1D), as well as adenosine and
the non-selective adenosine receptor agonist 5'-N-ethyl-
carboxamidoadenosine (NECA) (Fig. 1E). While beat fre-
quency increase was observed during 100 μM ATP
Table 1: List of drugs used
Abbreviatio
n
Full Name Site of Action*
αβmADP Adenosine 5'-(α,β-methylene)diphosphate Ecto-5'-nucleotidase inhibitor
Adenosine 9-β-D-Ribofuranosyladenine Nonselective adenosine receptor agonist
ATP Adenosine 5'-triphosphate P2 purinergic agonist
BBG Brilliant blue G P2X7 receptor antagonist
BzATP 2'(3')-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate triethylammonium salt P2X purinergic agonist; more potent than ATP at 
P2X7 receptors
CGS-21680 4-[2-[[6-Amino-9-(N-ethyl-b-D-ribofuranuronamidosyl)-9H-purin-2-
yl]amino]ethyl]benzenepropanoic acid hydrochloride
A2A adenosine receptor agonist
Dipyridamole 2,6-Bis(Diethanolamino)-4,8-dipiperidinopyrimido [5,4-d] pyrimidine Equlibrative nucleoside transporter inhibitor
IB-MECA 1-Deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-y l]-N-methyl-b-D-
ribofuranuronamide
Selective A3 adenosine receptor agonist
2'MeCCPA 2-Chloro-N-cyclopentyl-2'-methyladenosine Selective A1 adenosine receptor agonist
MRS 1754 N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-
8-yl)phenoxy]-acetamide
Selective adenosine A2B receptor antagonist
NBMPR S-(4-Nitrobenzyl)-6-thioinosine Equilibrative nucleoside transporter 1 inhibitor
NECA 5'-N-ethylcarboxamidoadenosine Nonselective adenosine receptor agonist.
Phloridzin Phloretin 2'-β-D-glucopyranoside Concentrative nucleoside transporter inhibitor
PSB 603 8-[4-[4-(4-Chlorophenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine Selective adenosine A2B receptor antagonist
Suramin 8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-me thyl-3,1-
phenylene)carbonylimino]]bis-1,3,5-naphthalene trisulfonic acid hexasodium 
salt
P2 antagonist (with broad subtype selectivity)
UTP Uridine 5'-triphosphate P2Y2/P2Y4 receptor agonist
* Selectivity depends on the concentration tested. Non-purinergic activities may also be present.Page 5 of 11
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monly used P2Y receptor antagonist suramin (200 μM)
did not reduce the ATP-induced increase in frequency
(Fig. 1D; 52.6 ± 4.8%). Furthermore, application of the
P2Y2/P2Y4 agonist UTP (Fig. 1D, 100 μM, 4.4 ± 3.2%) did
not induce a significant change in baseline frequency,
arguing against a role for these receptors in the ATP-
induced effect. Dose-response experiments (Fig. 1E)
showed that beat frequency increased with adenosine (1
μM, 18.7 ± 3.7%, n = 5; 10 μM, 35.1 ± 5.6%, n = 5; 30 μM,
67.9 ± 5.1%, n = 5; 60 μM, 56.5 ± 5.3%, n = 4) and with
NECA (100 nM, 9.4 ± 2.6%, n = 5; 1 μM, 41.9 ± 3.4%, n
= 8; 10 μM, 45.6 ± 5.1%, n = 4), and that NECA had a
greater potency than adenosine.
A2B receptors mediate adenosine and NECA-induced 
ciliary beat frequency enhancement
A cocktail of inhibitors for equilibrative (ENT) and con-
centrative (CNT) nucleoside transporters (1 mM phlo-
ridzin, 100 μM dipyridamole, 10 μM NBMPR; [23-25])
was not able to significantly reduce adenosine-induced
enhancement of beat frequency (Fig 2A; 26.3 ± 3.6%, P =
0.19), suggesting that neither influx nor efflux of adenos-
ine analogs is responsible for adenosine's effect on beat
frequency. Furthermore, selective (100 nM) concentra-
tions of the adenosine receptor agonists CGS 21680 (A2A;
2.7 ± 1.2%,), 2'MeCCPA (A1; 0.9 ± 3.4%,), or IB-MECA
(A3; -1.0 ± 2.5%) did not reveal any enhancement of beat
frequency (Fig. 2B) when compared to a no drug control
(-0.1 ± 2.4%). Loss of subtype selectivity precluded the
use of higher concentrations of these agonists for receptor
identification. As a selective A2B receptor agonist was not
commercially available [26], we tested two selective A2B
receptor antagonists for their ability to block the NECA-
induced enhancement of frequency. As shown in Fig. 2C,
MRS 1754 (100 nM; 7.1 ± 2.7%) and PSB 603 (1 μM; 1.3
± 2.0%) significantly blocked the increase in frequency
induced by 1 μM NECA. Furthermore, enhancement of
beat frequency by 300 μM BzATP was also significantly
reduced by MRS 1754 application (Fig. 2C; 12.4 ± 2.0%),
demonstrating that the previously observed BzATP
response is primarily due to A2B receptor activation. A
residual P2X7-mediated component cannot, however, be
excluded.
In Ca2+ imaging experiments, focal applications of 1 μM
NECA or 30 μM adenosine onto ependymal cells did not
induce a change in [Ca2+]i, thus suggesting that A2B-medi-
ated enhancement of beat frequency is not Ca2+-mediated
(Fig. 2D). Separate beat frequency experiments demon-
strated that 100 μM adenosine induces ciliary beat fre-
quency enhancement in EGTA (ethylene glycol-bis(2-
aminoethylether)-N, N, N', N'-tetraacetic acid)-buffered
Ca2+-free external solution (46.4 ± 8.2%, n = 2 slices, P <
0.05, data not shown), thereby supporting the conclusion
that A2B-mediated enhancement of beat frequency is not
Ca2+-mediated. Finally, as a positive control (and consist-
ent with prior observations from our laboratory [17]),
300 μM BzATP-induces a dramatic increase in [Ca2+]i (Fig.
2D).
Histochemical and functional evidence for A2B expression: 
immunocytochemistry and A2B-/-/β-gal reporter gene 
knock-in mice
We next sought to confirm A2B expression by ependymal
cells using immunocytochemical methods. While distinct
A2B immunoreactivity was observed in ependymal cells
(Fig. 3A), non-selective nuclear staining was also observed
throughout the central nervous system (CNS) and there-
fore precluded definitive interpretation. Two additional
A2B antibodies did not show any CNS labeling (data not
shown). A2A immunoreactivity was evident in the striatum
and in a scattered distribution along the SVZ but not in
ependymal cells (Fig. 3B). An alternative approach was
therefore used as a verification of the presence of A2B
receptors.
Previously characterized A2B-/-/β-gal reporter gene knock-
in mice [19] were surveyed for A2B gene promoter-driven
expression of β-galactosidase in ependymal cells along the
lateral ventricle. Strong X-gal reaction product was
observed in the lateral septal nucleus, and clear intracellu-
lar labeling was also visible in ependymal cells and scat-
tered throughout the cortex and striatum (Fig. 3C). This
pattern was observed in A2B-/-/β-gal mice but not in wild-
type controls. β-gal immunoreactivity was also observed
in the A2B-/-/β-gal mice in S100β-positive ependymal cells
(Fig. 3D-F), providing an additional layer of evidence for
A2B expression by ependyma. Ependymal X-gal reaction
product is also visible in the corresponding Fig. 3G.
Functional evidence for A2B expression by ependymal cells
was also observed in the A2B-/-/β-gal mice (Fig. 4). Neither
NECA (1 μM; -1.3 ± 1.8%) nor adenosine (30 μM; 4.0 ±
1.9%) was capable of increasing ciliary beat frequency in
the A2B-/-/β-gal mice (Fig. 4A). BzATP, however, induces a
significant (Fig. 4B), albeit smaller, enhancement of beat
frequency in A2B-/-/β-gal mice (36.6 ± 3.0%) versus wild-
type controls (58.9 ± 3.4%, data also in Fig. 1C). The
increase induced by BzATP in the A2B-/-/β-gal mice is com-
pletely blocked by pre-incubation with the P2X7 antago-
nist BBG (Fig. 4B; 0.8 ± 2.2%), thus providing additional
evidence for a residual P2X7-mediated enhancement in
these animals. A summary diagram is presented in Fig. 4C.
Discussion
The present experiments demonstrated that activation of
the adenosine A2B receptor enhanced ciliary beat fre-
quency in mouse lateral ventricle ependymal cells - a con-
clusion supported by pharmacological experiments usingPage 6 of 11
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Adenosine-mediated enhancement of ciliary beat frequency is due to A2B receptor activation. (A) Histogram
showing that ciliary beat frequency enhancement was not eliminated by pre-incubation with a cocktail of CNT and ENT inhibi-
tors (1 mM phloridzin, 100 μM dipyridamole, 10 μM NBMPR; n = 5). (B) Summary histogram showing that ciliary beat fre-
quency did not increase in response to a no drug control (Cont., n = 10), nor selective concentrations of the A2A agonist CGS
21680 (100 nM, n = 5), the A1 agonist 2'MeCCPA (100 nM, n = 5), nor the A3 agonist IB-MECA (100 nM, n = 5). There was no
significant difference between the no drug control and CGS 21680, 2'MeCCPA, or IB-MECA. (C) Histogram demonstrating
that the response to 1 μM NECA was significantly reduced by the A2B antagonist MRS 1754 (100 nM, n = 9) and eliminated by
the A2B antagonist PSB 603 (1 μM, n = 10). Response to 300 μM BzATP was also reduced by MRS 1754 (100 nM, n = 8). (D)
[Ca2+]i was increased by 1 min focal application (↓) of 300 μM BzATP ([Black circle], n = 1 application/10 regions of interest),
but not by 3 min applications of 1 μM NECA (❍, n = 3 applications/30 regions of interest) or 30 μM adenosine, (, n = 3 appli-
cations/30 regions of interest): note: ❍ and  symbols largely overlap. The percent change in fluorescence signal divided by
baseline mean fluorescence intensity is shown in the Y-axis (%ΔF/F0). *: P < 0.05 for all panels, data are means ± SEM. The n
value indicates the number of slices tested.
selective adenosine receptor agonists and antagonists, as
well as experiments using the A2B-/-/β-gal mice. The fact
that BzATP application onto mouse brain slices can lead
to activation of a non-P2X7-mediated pathway is not sur-
prising. For example, prior studies in the hippocampus
have demonstrated that BzATP can induce non-P2X7-
mediated effects through the action of ecto-nucleotidases,
nucleoside transporters, and subsequent adenosine recep-
tor activation [27]. Ependymal cells have been shown to
express ecto-nucleotide pryrophasphatase/phosphodi-
esterase 1 (NPP1) and ecto-5'-nucleotidase [28,29], and
the decrease in BzATP-mediated effects after pre-incuba-
tion with αβmADP (an ecto-5'-nucleotidase inhibitor; Fig.
1C) suggests that ciliary beat frequency enhancement isPage 7 of 11
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Ependymal localization of A2B: evidence from immunocytochemistry and X-gal staining. (A) Cytoplasmic A2B-
immunoreactivity was evident in ependymal cells (see inset) of wild type mice, although non-specific nuclear labeling was also 
evident throughout the brain and confounds interpretation of ependymal immunoreactivity. (B) No labeling of ependymal cells 
was observed using an antibody to A2A receptors in wild type mice, although strong immunoreactivity was evident in the stria-
tum and in a scattered distribution along the SVZ. (C) DIC image from an A2B-/-/β-gal reporter gene knock-in mouse showing 
darkening of cells due to X-gal precipitate in regions surrounding the ependymal layer (e). Strong X-gal labeling was observed 
in the lateral septal nucleus (ls), while scattered labeling was observed in the striatum (st) and cortex (ctx) but not in the corpus 
callosum (cc). The septum mechanically separated from the corpus callosum during the staining procedure, thus obliterating 
the dorso-medial boundary of the lateral ventricle (lv) in this slice. (Bar = 500 μm). (D-F) Immunocytochemistry from an A2B-/-/β-gal reporter gene knock-in mouse demonstrating that β-galactosidase (D; green, Bar = 25 μm) and S100β (E, red) are co-
localized in ependymal cells (F). Nuclei are stained with DAPI (blue). (G) Corresponding DIC image with darkening of the 
ependyma due to X-gal precipitate.
largely dependent on a metabolic breakdown product
rather than BzATP itself.
It should be noted that BBG was used as the sole P2X7
antagonist in these studies, as the more commonly used
adenosine 5'triphosphate-2',3'-dialdehyde (oATP)
induced toxicity in prior experiments (unpublished obser-
vations) and KN-62 has demonstrated a weaker activity at
mouse versus human P2X7 receptors [30]. Our recent
whole-cell patch clamp experiments, however, showed
clear antagonism of ependymal cell BzATP-induced cur-
rents by low concentrations of BBG [17]. Furthermore, no
additional P2X receptor subtypes were detected during
patch clamp recordings of P2X7-/- mice [17]. While data in
Fig. 1C, Fig. 2C, and Fig. 4B argue that a minor P2X7-
mediated component to BzATP-induced ciliary beat fre-
quency enhancement is present, it is most easily observed
in the absence of the adenosine A2B receptor (Fig. 4B).
The lack of ciliary beat frequency enhancement with 100
μM UTP (Fig. 1D), and the absence of a suramin-mediated
antagonism of ATP-induced changes in beat frequency
(Fig. 1D), strongly argue against a P2Y-mediated modula-
tion of frequency in the present experiments. These data
do not altogether eliminate the possibility, however, that
another subtype of P2Y-receptor may play a role in beat
frequency modulation. A more extensive pharmacological
analysis (with inclusion of appropriate ecto-nucleotidase
inhibitors to prevent breakdown of purinergic drugs into
adenosine receptor agonists) is clearly desirable and
should be the focus of future investigation.
Interestingly, ATP has previously been shown to decrease
ciliary beat frequency in rat 4th ventricle ependymal cells
[14]. It is reasonable to assume that species and region-
specific differences may exist in ependymal cell response
to ATP, which is obviously dependent on the subtypes of
purinergic receptors expressed. For example, in our mouse
lateral ventricle ependymal cells, [Ca2+]i increases rapidly
after BzATP application (Fig. 2D and [17]); this is in sharp
contrast to ATP's lack of [Ca2+]i effect in the previously
mentioned rat experiments [14]. Other proteins expressed
by ependyma during development - such as glial fibrillary
acidic protein (GFAP) and vimentin - vary markedly
between species, developmental stage, and location along
the ventricular system [31]. Future work on anatomic asPage 8 of 11
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Ciliary beat frequency analysis in A2B-/-/β-gal reporter gene knock-in mice. (A) Histogram showing the absence of cil-
iary beat frequency enhancement due to 1 μM NECA (n = 10) and 30 μM adenosine (n = 10) in the A2B-/- mice. (B) Enhance-
ment due to 300 μM BzATP application was reduced in the A2B-/- mice (n = 8) versus wild-type P2X7+/+ mice (n = 5). BzATP-
induced enhancement was eliminated in the A2B-/- mice after pre-incubation of the slices with 100 nM BBG (n = 8). *: P < 0.05 
for all panels, data are means ± SEM. The n value indicates the number of slices tested. (C) Summary diagram showing enzy-
matic breakdown of BzATP and subsequent receptor activation. ATP (an endogenous signaling molecule analogous to BzATP) 
is shown in grey.
well as species-specific differences in ependymal cell cili-
ary beat frequency regulation is clearly warranted.
A2B can be coupled to multiple G-protein cascades, includ-
ing the adenylate cyclase (Gs; cAMP) pathway and the
phospholipase C (Gq11) signaling pathways [32-35]. Fur-
thermore, activation of the phospholipase C - mediated
pathway can lead to [Ca2+]i increases after A2B activation
[32]. In the present experiments, however, neither NECA
(1 μM) nor adenosine (30 μM) were able to induce [Ca2+]i
increases in ependymal cells (Fig. 2D), arguing against a
Ca2+-mediated mechanism for A2B-induced enhancement
of ciliary beat frequency. While additional pathways
involved in A2B-mediated signaling were not explored in
the present experiments, a complete understanding of
these pathways may prove critical for determining the
importance of receptor signaling cascades in CSF dynam-
ics. For example, a recent study by Mönkkönen et al.
(2007) has demonstrated that knockdown of Gαi2 can
lead to ciliary stasis and ventricular dilation [11].
Nucleotide signaling and purinergic receptor expression
in the developing brain has been the subject of intense
investigation (for review, see [36]). For example, the
developmental precursors of ependyma - radial glia [37] -
can propagate ATP-mediated Ca2+ waves that are depend-
ent on P2Y1 receptor expression [38]. Immature epend-
yma are born between embryonic days E14 and E16 in the
mouse, although cell maturation and cilia formation typ-
ically occur during the first postnatal week [37]. Little isPage 9 of 11
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tors on these cells during this time. It should also be noted
that neuroblast migration from the SVZ to the rostral
migratory stream depends on the normal flow of CSF, and
ciliary motility is required for maintaining a diffusional
gradient of inhibitory guidance molecules in the CSF [39].
Whether receptor-mediated changes in ciliary beat fre-
quency play a role in this phenomenon is not known.
Purinergic receptor expression on CSF secreting cells of
the choroid plexus has also been the subject of recent
investigations [40,41].
Additional questions clearly remain to be answered. Is the
source of endogenous ATP or adenosine autocrine or
paracrine? Does ciliary beat frequency correlate with the
metabolic requirements in the CNS, and might ciliary
beat frequency dysregulation be associated with hydro-
cephalus? While answers to these questions are beyond
the scope of the present experiments, much remains to be
learned about the role of purinergic receptors and ciliary
beat frequency in cerebral fluid dynamics.
Conclusion
While abnormal ciliary structure and function has been
associated with hydrocephalus in several experimental
models, the signaling mechanisms responsible for the
normal regulation of ependymal cell ciliary beat fre-
quency are not well understood. The present experiments
demonstrate that activation of the adenosine A2B receptor
enhances ciliary beat frequency in lateral ventricle epend-
ymal cells. A residual contribution of purinergic P2X7
receptors to frequency regulation is also supported. Purin-
ergic modulation of ependymal cell beat frequency may
play an important role in maintaining normal fluid bal-
ance in the CNS. Future experiments should focus on
understanding whether purinergic dysregulation contrib-
utes to pathologic conditions such as hydrocephalus.
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